The global cell expansion market was valued at $14.9 billion in 2020 and is projected to reach $30.1 billion by 2025, growing at a compound annual growth rate (CAGR) of 15.1% during that period, according to a new report from MarketsandMarkets Research. Key factors driving this growth include rising chronic disease prevalence, increased government funding for cell research, and a focus on personalized medicine and cell therapies.
The consumables products segment accounted for the largest market share in 2019. This includes reagents, media, sera and disposables like tissue culture flasks and pipettes. The high usage of consumables in vaccine and biologics manufacturing for the biopharma and biotech industries is contributing to the dominant position of this segment.
Based on application, regenerative medicine and stem cell research made up the greatest portion of the cell expansion industry in 2019. This is attributed to expanded financing for work in these areas. Researchers utilize cell expansion techniques to derive sufficient cells for therapies targeting conditions like diabetes, cancer, immune disorders and neurological diseases.
Human cells commanded the largest share among cell types, thanks to substantial investments by public and private institutions in human cell research. Additionally, the escalating occurrence of cancer and other predominant diseases necessitates studies utilizing human cells. Adult stem cells, embryonic stem cells, and induced pluripotent stem cells are included in the human stem cell subset.
Geographically, North America led the global industry in 2019. Variables such as high cancer frequency, government backing of research, and an established network of major market competitors based in the region underlie its premier market position. The United States particularly contributes to North America’s substantial portion of revenue.
Some major players operating globally include Thermo Fisher Scientific, Danaher, Becton Dickinson, Lonza, Corning Inc., Merck KGaA , Miltenyi Biotec, STEMCELL Technologies Inc., Sartorius AG and Terumo Corporation. Savvy companies are utilizing strategic moves like facility expansions, partnerships, and mergers and acquisitions to augment market share while serving increasing cell therapy manufacture demand.
In summary, the soaring prevalence of chronic and deadly diseases coupled with other key trends bodes very well for global cell expansion market growth through 2025. Superior treatment accessibility worldwide should result from the flourishing R&D activities centered on personalized medicine and innovative cell therapies.